Novozymes A/S (NVZMF)
| Previous close | 61.30 |
| Open | 61.90 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 61.35 - 62.65 |
| 52-week range | 54.65 - 82.59 |
| Volume | |
| Avg. volume | 1,146 |
| Market cap | 17.246B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 42.57 |
| EPS (TTM) | 1.46 |
| Earnings date | N/A |
| Forward dividend & yield | 0.82 (1.28%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Globe Newswire
Novozymes delivers strong half year results and narrows full-year outlook upwards
Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%. COPENHAGEN, Denmark – August 11, 2022. Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK. Good mome
- Globe Newswire
Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost
Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented. COPENHAGEN, Denmark – 15 July 2022. Novozymes has been able to partially shield its customers from a large part of the global challenges, securing business continuity and high price stability relative to other suppliers. However, Novozymes will further substantially increase prices at a level at least in line with the current
- Zacks
AXTA vs. NVZMY: Which Stock Is the Better Value Option?
AXTA vs. NVZMY: Which Stock Is the Better Value Option?
